“That’s why it’s important to fund vaccine research. You never know where the next pandemic will come from.”
Louis Falo, professor and chair of dermatology at Pitt’s School of Medicine and co-senior author, added: “Our ability to rapidly develop this vaccine was a result of scientists with expertise in diverse areas of research working together with a common goal.”
The vaccine described in this paper has been dubbed by the authors as PittCoVacc, short for Pittsburgh Coronavirus Vaccine
Compared to the experimental mRNA vaccine candidate that just entered clinical trials, PittCoVacc follows a more established approach.
The researchers created PittCoVacc using lab-made pieces of a viral protein to build immunity, in a similar way to how the current flu shots work.